On July 23rd, 2pm EDT in a Virtual Launch Event, Insilico is going to unveil three innovative in-house developed AI products for researchers as well as introduce the updates to https://bit.ly/4f0noIv the company’s proprietary #generativeAI-driven platform for early #drugresearch. In addition, we will introduce our new advanced sustainability initiative driven by AI. The event will include a Q&A session for attendees.
Currently, 10 of the world's top 20 #pharmaceutical companies use https://bit.ly/3Y4NzI6 Powered by the platform, Insilico has nominated 18 #preclinical candidates in its comprehensive portfolio of over 30 assets since 2021, and has received IND approval for 7 molecules. Recently, the company published a paper in Nature Biotechnology presenting the entire R&D journey of its lead drug pipeline, INS018_055, from AI algorithms to Phase II #clinicaltrials.
“At Insilico, we are committed to continually expanding the boundaries of AI applications and applying them to all aspects of life sciences to accelerate drug discovery, empower anti-aging research, and support sustainable development,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine, “ These new product launches are expected to help life science researchers accomplish their tasks more easily and efficiently. This is the true promise of genAI.”
Read the full release here: https://bit.ly/3Y3ozkh